Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer

[1]  Daniel J Sargent,et al.  A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[3]  K. Muro,et al.  Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  M. Jeffery,et al.  Follow-up strategies for patients treated for non-metastatic colorectal cancer. , 2016, The Cochrane database of systematic reviews.

[5]  A. Orlandi,et al.  Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope. , 2015, The oncologist.

[6]  G. Fontanini,et al.  FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. , 2015, The Lancet. Oncology.

[7]  B. Massuti,et al.  First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours. , 2015, European journal of cancer.

[8]  B. Vogelstein,et al.  PD-1 blockade in tumors with mismatch repair deficiency. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Marc Peeters,et al.  Randomized trial of TAS-102 for refractory metastatic colorectal cancer. , 2015, The New England journal of medicine.

[10]  E. Van Cutsem,et al.  Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. , 2015, The Lancet. Oncology.

[11]  C. Boni,et al.  Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. , 2014, The New England journal of medicine.

[12]  K. Sugihara,et al.  Prognostic factors for peritoneal carcinomatosis originating from colorectal cancer: an analysis of 921 patients from a multi-institutional database , 2014, Surgery Today.

[13]  K. Shirouzu,et al.  Clinical benefit of surgery for stage IV colorectal cancer with synchronous peritoneal metastasis , 2014, Journal of Gastroenterology.

[14]  D. Mirza,et al.  Repeat liver resection for recurrent colorectal metastases: a single-centre, 13-year experience. , 2014, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[15]  K. Sugihara,et al.  Outcomes of surgery without HIPEC for synchronous peritoneal metastasis from colorectal cancer: data from a multi-center registry , 2014, International Journal of Clinical Oncology.

[16]  J. Meyerhardt,et al.  Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Kazuhiro Yoshida,et al.  Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. , 2013, The Lancet. Oncology.

[18]  R. Parks,et al.  Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. , 2013, The Lancet. Oncology.

[19]  R. Labianca,et al.  Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  Elie A Akl,et al.  GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. , 2013, Journal of clinical epidemiology.

[21]  Susan Richman,et al.  Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial , 2013, The Lancet. Oncology.

[22]  N. Ikeda,et al.  Prognostic Factors After Pulmonary Metastasectomy for Colorectal Cancer and Rationale for Determining Surgical Indications: A Retrospective Analysis , 2013, Annals of surgery.

[23]  T. Ohnuki,et al.  Prognostic factors in patients undergoing complete resection of pulmonary metastases of colorectal cancer: a multi-institutional cumulative follow-up study , 2013, Surgery Today.

[24]  A. Doeksen,et al.  Intentionally curative treatment of locally recurrent rectal cancer: a systematic review. , 2013, Canadian journal of surgery. Journal canadien de chirurgie.

[25]  S. Kudo,et al.  Current status of endoscopic resection strategy for large, early colorectal neoplasia in Japan , 2013, Surgical Endoscopy.

[26]  K. Kaneko,et al.  Long-term outcomes after resection for submucosal invasive colorectal cancers. , 2013, Gastroenterology.

[27]  G. Guyatt,et al.  GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles-continuous outcomes. , 2013, Journal of clinical epidemiology.

[28]  Gordon H Guyatt,et al.  GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes. , 2013, Journal of clinical epidemiology.

[29]  Elie A Akl,et al.  GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. , 2013, Journal of clinical epidemiology.

[30]  C. Combescure,et al.  Risk Factors for Survival after Lung Metastasectomy in Colorectal Cancer Patients: A Systematic Review and Meta-Analysis , 2013, Annals of Surgical Oncology.

[31]  D. Sargent,et al.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.

[32]  D. Goldstein,et al.  Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  T. Conroy,et al.  Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  N. Sugimoto,et al.  TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. , 2012, The Lancet. Oncology.

[35]  R. Labianca,et al.  ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  E. Van Cutsem,et al.  Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  M. Yano,et al.  Brain metastasis from colorectal cancer: Prognostic factors and survival , 2012, Journal of surgical oncology.

[38]  Torsten Hothorn,et al.  Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. , 2012, The Lancet. Oncology.

[39]  M. Ohue,et al.  Postoperative morbidity and mortality after mesorectal excision with and without lateral lymph node dissection for clinical stage II or stage III lower rectal cancer (JCOG0212): results from a multicentre, randomised controlled, non-inferiority trial. , 2012, The Lancet. Oncology.

[40]  P. Kienle,et al.  Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. , 2012, The Lancet. Oncology.

[41]  T. Muto,et al.  Results of a Japanese Nationwide Multi-Institutional Study on Lateral Pelvic Lymph Node Metastasis in Low Rectal Cancer: Is It Regional or Distant Disease? , 2012, Annals of surgery.

[42]  H. Heneghan,et al.  Systematic review of outcomes after intersphincteric resection for low rectal cancer , 2012, The British journal of surgery.

[43]  Xianghua Luo,et al.  Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  Gordon H Guyatt,et al.  GRADE guidelines: 9. Rating up the quality of evidence. , 2011, Journal of clinical epidemiology.

[45]  Gordon H Guyatt,et al.  GRADE guidelines: 5. Rating the quality of evidence--publication bias. , 2011, Journal of clinical epidemiology.

[46]  G. Guyatt,et al.  GRADE guidelines 6. Rating the quality of evidence--imprecision. , 2011, Journal of clinical epidemiology.

[47]  Y. Shimada,et al.  Intramural and Mesorectal Distal Spread Detected by Whole-Mount Sections in the Determination of Optimal Distal Resection Margin in Patients Undergoing Surgery for Rectosigmoid or Rectal Cancer Without Preoperative Therapy , 2011, Diseases of the colon and rectum.

[48]  N. Petrelli,et al.  Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  Y. Kakeji,et al.  Genotype‐directed, dose‐finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms , 2011, Cancer science.

[50]  M. Higashiyama,et al.  Outcome of surgical resection for recurrent pulmonary metastasis from colorectal carcinoma. , 2011, American journal of surgery.

[51]  Toshiaki Watanabe.  The Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer (The 49th annual meeting of Japanese Society of Clinical Oncology educational book) -- (JSCO University: Colorectal cancers) , 2011 .

[52]  H. Ikematsu,et al.  Risk of lymph node metastasis in patients with pedunculated type early invasive colorectal cancer: A retrospective multicenter study , 2011, Cancer science.

[53]  R. Chamberlain,et al.  Gastrointestinal cancer and brain metastasis , 2011, Cancer.

[54]  L. Boni,et al.  Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  Hein Putter,et al.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. , 2011, The Lancet. Oncology.

[56]  N. Petrelli,et al.  The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  F. D. De Braud,et al.  Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  Gordon H Guyatt,et al.  GRADE guidelines: 2. Framing the question and deciding on important outcomes. , 2011, Journal of clinical epidemiology.

[59]  G. Guyatt,et al.  GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. , 2011, Journal of clinical epidemiology.

[60]  S. Kudo,et al.  MID‐TERM PROGNOSIS AFTER ENDOSCOPIC RESECTION FOR SUBMUCOSAL COLORECTAL CARCINOMA: SUMMARY OF A MULTICENTER QUESTIONNAIRE SURVEY CONDUCTED BY THE COLORECTAL ENDOSCOPIC RESECTION STANDARDIZATION IMPLEMENTATION WORKING GROUP IN JAPANESE SOCIETY FOR CANCER OF THE COLON AND RECTUM , 2011, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society.

[61]  G. Guyatt,et al.  GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias). , 2011, Journal of clinical epidemiology.

[62]  Howard Balshem,et al.  GRADE guidelines: 3. Rating the quality of evidence. , 2011, Journal of clinical epidemiology.

[63]  Y. Yatabe,et al.  BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer , 2011, British Journal of Cancer.

[64]  M. Moore,et al.  A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining , 2011, Investigational New Drugs.

[65]  Kinichi Hotta,et al.  A prospective, multicenter study of 1111 colorectal endoscopic submucosal dissections (with video). , 2010, Gastrointestinal endoscopy.

[66]  J. Stoker,et al.  Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment. , 2010, Radiology.

[67]  Josep Tabernero,et al.  Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  E. Van Cutsem,et al.  Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  M. Choti,et al.  Disappearing Colorectal Liver Metastases after Chemotherapy: Should we be Concerned? , 2010, Journal of Gastrointestinal Surgery.

[70]  I. Hyodo,et al.  Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). , 2010, The Lancet. Oncology.

[71]  M. Stockler,et al.  Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  J. Tabernero,et al.  Randomized phase III study of panitumumab (pmab) with FOLFOX4 compared to FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): PRIME trial analysis by epidermal growth factor receptor (EGFR) tumor staining. , 2010 .

[73]  A. Santoro,et al.  Randomized phase III study of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis by tumor epidermal growth factor receptor (EGFR) staining. , 2010 .

[74]  Christophe Hennequin,et al.  Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  M. D'Angelica,et al.  Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy , 2010, Cancer.

[76]  Yuman Fong,et al.  American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  Dong Han Lee,et al.  Stereotactic body radiotherapy for isolated paraaortic lymph node recurrence from colorectal cancer. , 2009, World journal of gastroenterology.

[78]  E. Van Cutsem,et al.  Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. , 2009, The New England journal of medicine.

[79]  J. Lim,et al.  Extended Lymph Node Dissection for Rectal Cancer with Radiologically Diagnosed Extramesenteric Lymph Node Metastasis , 2009, Annals of Surgical Oncology.

[80]  K. Nagai,et al.  Factors influencing survival after complete resection of pulmonary metastases from colorectal cancer , 2009, The British journal of surgery.

[81]  J. Tabernero,et al.  5LBA First efficacy findings from a randomized phase III trial of capecitabine + oxaliplatin vs. bolus 5-FU/LV for stage III colon cancer (NO16968/XELOXA study) , 2009 .

[82]  J. Tabernero,et al.  10LBA Randomized phase 3 study of panitumumab with FOLFOX4 compared to FOLFOX4 alone as 1st-line treatment (tx) for metastatic colorectal cancer (mCRC): the PRIME trial , 2009 .

[83]  T. Hickish,et al.  Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  Kazutaka Yamada,et al.  Long-Term Results of Intersphincteric Resection for Low Rectal Cancer , 2009, Diseases of the colon and rectum.

[85]  A. Horvath,et al.  Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. , 2009, Clinical chemistry.

[86]  Yoichi Tanaka,et al.  Microsatellite instability-low colorectal cancer acquires a KRAS mutation during the progression from Dukes' A to Dukes' B. , 2009, Carcinogenesis.

[87]  A. Piga,et al.  Neurosurgical management and postoperative whole-brain radiotherapy for colorectal cancer patients with symptomatic brain metastases , 2009, Journal of Cancer Research and Clinical Oncology.

[88]  C. Bokemeyer,et al.  Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  Dongsheng Tu,et al.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.

[90]  R. Labianca,et al.  Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[91]  Y. Bang,et al.  Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[92]  Shinji Tanaka,et al.  Colorectal endoscopic submucosal dissection: present status and future perspective, including its differentiation from endoscopic mucosal resection , 2008, Journal of Gastroenterology.

[93]  G. Guyatt,et al.  Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive , 2008, BMJ : British Medical Journal.

[94]  Gordon H Guyatt,et al.  Incorporating considerations of resources use into grading recommendations , 2008, BMJ : British Medical Journal.

[95]  M. Miyazaki,et al.  Interval Period Tumor Progression: Does Delayed Hepatectomy Detect Occult Metastases in Synchronous Colorectal Liver Metastases? , 2008, Journal of Gastrointestinal Surgery.

[96]  W. Scheithauer,et al.  EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[97]  G. Guyatt,et al.  Going from evidence to recommendations , 2008, BMJ : British Medical Journal.

[98]  Gordon H Guyatt,et al.  GrADe : what is “ quality of evidence ” and why is it important to clinicians ? rATING quALITY of evIDeNCe AND STreNGTH of reCommeNDATIoNS , 2022 .

[99]  E. Van Cutsem,et al.  Colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[100]  P. Laurent-Puig,et al.  KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[101]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[102]  W. Scheithauer,et al.  Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[103]  W. Scheithauer,et al.  Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[104]  F. Lévi,et al.  Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[105]  Daniel J. Freeman,et al.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[106]  N. Kim,et al.  Isolated paraaortic lymph‐node recurrence after the curative resection of colorectal carcinoma , 2008, Journal of surgical oncology.

[107]  A. Lièvre,et al.  KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[108]  H. Putter,et al.  The TME Trial After a Median Follow-up of 6 Years: Increased Local Control But No Survival Benefit in Irradiated Patients With Resectable Rectal Carcinoma , 2007, Annals of surgery.

[109]  C. Fuchs,et al.  Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[110]  C. Marijnen,et al.  Risk factors for faecal incontinence after rectal cancer treatment , 2007, The British journal of surgery.

[111]  J. Tjandra,et al.  Follow-Up After Curative Resection of Colorectal Cancer: A Meta-Analysis , 2007, Diseases of the colon and rectum.

[112]  M. Gonen,et al.  Outcomes after resection of synchronous or metachronous hepatic and pulmonary colorectal metastases. , 2007, Journal of the American College of Surgeons.

[113]  N. Petrelli,et al.  Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[114]  Manuel Hidalgo,et al.  Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[115]  Marc Peeters,et al.  Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[116]  L. Crinò,et al.  Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[117]  P. Catalano,et al.  Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[118]  R. Adam.  Developing strategies for liver metastases from colorectal cancer. , 2007, Seminars in oncology.

[119]  U. Neumann,et al.  Repeat liver resection for recurrent liver metastases from colorectal cancer. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[120]  T. Frebourg,et al.  Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy , 2007, British Journal of Cancer.

[121]  S. Yoshida,et al.  An individual patient data meta-analysis of adjuvant therapy with uracil–tegafur (UFT) in patients with curatively resected rectal cancer , 2007, British Journal of Cancer.

[122]  H. Ueno,et al.  Potential Prognostic Benefit of Lateral Pelvic Node Dissection for Rectal Cancer Located Below the Peritoneal Reflection , 2007, Annals of surgery.

[123]  J. Bosset,et al.  Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[124]  K. Shirouzu,et al.  Indication and Benefit of Pelvic Sidewall Dissection for Rectal Cancer , 2006, Diseases of the colon and rectum.

[125]  J. Yamamoto,et al.  Surgical resection of pulmonary metastases from colorectal cancer: Four favourable prognostic factors. , 2006, Japanese journal of clinical oncology.

[126]  K. Bujko,et al.  Long‐term results of a randomized trial comparing preoperative short‐course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer , 2006, The British journal of surgery.

[127]  Bernard Leduc,et al.  Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[128]  Shinji Tanaka,et al.  High-magnification colonoscopy (with videos). , 2006, Gastrointestinal endoscopy.

[129]  Y. Sakamoto,et al.  Second Hepatectomy for Recurrent Colorectal Liver Metastasis: Analysis of Preoperative Prognostic Factors , 2006, Annals of Surgical Oncology.

[130]  Laurence Collette,et al.  Chemotherapy with preoperative radiotherapy in rectal cancer. , 2006, The New England journal of medicine.

[131]  Catherine Julié,et al.  Complete response of colorectal liver metastases after chemotherapy: does it mean cure? , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[132]  K. Hiroshima,et al.  Prediction of prognosis and surgical indications for pulmonary metastasectomy from colorectal cancer. , 2006, The Annals of thoracic surgery.

[133]  Hiroki Shirato,et al.  Stereotactic Radiosurgery Plus Whole-Brain Radiation Therapy vs Stereotactic Radiosurgery Alone for Treatment of Brain Metastases: A Randomized Controlled Trial , 2007 .

[134]  N. Petrelli,et al.  Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[135]  A. Lièvre,et al.  KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.

[136]  A. Mellgren,et al.  Long-Term Effect of Preoperative Radiation Therapy on Anorectal Function , 2006, Diseases of the colon and rectum.

[137]  F. Luo,et al.  Hypoxia-inducible transcription factor-1α promotes hypoxia-induced A549 apoptosis via a mechanism that involves the glycolysis pathway , 2006, BMC Cancer.

[138]  P. Catalano,et al.  Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[139]  Bruce D Minsky,et al.  Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[140]  C. V. D. van de Velde,et al.  Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients--a Dutch colorectal cancer group study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[141]  Markus Abt,et al.  Capecitabine as adjuvant treatment for stage III colon cancer. , 2005, The New England journal of medicine.

[142]  T. Muto,et al.  Incidence and prognostic significance of lateral lymph node metastasis in patients with advanced low rectal cancer , 2005, The British journal of surgery.

[143]  N. Wolmark,et al.  A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Survival results of NSABP Protocol C-07 , 2005 .

[144]  J. Berlin,et al.  Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[145]  H. Putter,et al.  Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[146]  M. Egger,et al.  Mechanisms of improved survival from intensive followup in colorectal cancer: a hypothesis , 2005, British Journal of Cancer.

[147]  Rong Wang,et al.  Pathological study of distal mesorectal cancer spread to determine a proper distal resection margin. , 2005, World journal of gastroenterology.

[148]  G. Guyatt,et al.  Systems for grading the quality of evidence and the strength of recommendations I: Critical appraisal of existing approaches The GRADE Working Group , 2004, BMC health services research.

[149]  Richard L Schilsky,et al.  Cetuximab in the treatment of colorectal cancer. , 2004, Clinical advances in hematology & oncology : H&O.

[150]  Rainer Fietkau,et al.  Preoperative versus postoperative chemoradiotherapy for rectal cancer. , 2004, The New England journal of medicine.

[151]  I. Hyodo,et al.  Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[152]  M. Somerfield,et al.  American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[153]  Hidetaka Mochizuki,et al.  Risk factors for an adverse outcome in early invasive colorectal carcinoma. , 2004, Gastroenterology.

[154]  Armando Santoro,et al.  Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.

[155]  T. Hickish,et al.  Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. , 2004, The New England journal of medicine.

[156]  Toshihide Kumamoto,et al.  Correlations between lymph node metastasis and depth of submucosal invasion in submucosal invasive colorectal carcinoma: a Japanese collaborative study , 2004, Journal of Gastroenterology.

[157]  Kenneth Hess,et al.  Recurrence and Outcomes Following Hepatic Resection, Radiofrequency Ablation, and Combined Resection/Ablation for Colorectal Liver Metastases , 2004, Annals of surgery.

[158]  Maria Werner-Wasik,et al.  Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial , 2004, The Lancet.

[159]  I. Endo,et al.  Procedures of Choice for Resection of Primary and Recurrent Liver Metastases from Colorectal Cancer , 2004, World Journal of Surgery.

[160]  C. Tournigand,et al.  FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[161]  Tomoyuki Kato,et al.  Preoperative probability model for predicting overall survival after resection of pulmonary metastases from colorectal cancer , 2004, The British journal of surgery.

[162]  C. Earle,et al.  Follow-up of patients with curatively resected colorectal cancer: a practice guideline , 2003, BMC Cancer.

[163]  Takeo Mori,et al.  Therapeutic Results for Hepatic Metastasis of Colorectal Cancer With Special Reference to Effectiveness of Hepatectomy: Analysis of Prognostic Factors for 763 Cases Recorded at 18 Institutions , 2003, Diseases of the colon and rectum.

[164]  J. Berlin,et al.  Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[165]  Takanobu Kobayashi,et al.  Pulmonary metastasectomy for 165 patients with colorectal carcinoma: A prognostic assessment. , 2002, The Journal of thoracic and cardiovascular surgery.

[166]  B. Nordlinger,et al.  Colorectal metastasis (liver and lung). , 2002, The Surgical clinics of North America.

[167]  A. Oza,et al.  Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[168]  J. Douillard,et al.  Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[169]  J. Pekolj,et al.  Simultaneous colorectal and hepatic resections for colorectal cancer: postoperative and longterm outcomes. , 2002, Journal of the American College of Surgeons.

[170]  Yoshihiro Sakamoto,et al.  Genetic and histological assessment of surgical margins in resected liver metastases from colorectal carcinoma: minimum surgical margins for successful resection. , 2002, Archives of surgery.

[171]  K. Sugihara,et al.  Discontinuous Rectal Cancer Spread in the Mesorectum and the Optimal Distal Clearance Margin in Situ , 2002, Diseases of the colon and rectum.

[172]  M. Gonen,et al.  Second Liver Resections Are Safe and Effective Treatment for Recurrent Hepatic Metastases from Colorectal Cancer: A Bi-institutional Analysis , 2002, Annals of surgery.

[173]  J. Kievit.  Follow-up of patients with colorectal cancer: numbers needed to test and treat. , 2002, European journal of cancer.

[174]  M. Egger,et al.  Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials , 2002, BMJ : British Medical Journal.

[175]  H. Shimada,et al.  Results of Aggressive Resection of Lung Metastases from Colorectal Carcinoma Detected by Intensive Follow-Up , 2002, Diseases of the colon and rectum.

[176]  P. Catalano,et al.  Surveillance for Second Primary Colorectal Cancer after Adjuvant Chemotherapy: An Analysis of Intergroup 0089 , 2002, Annals of Internal Medicine.

[177]  K. Hatakeyama,et al.  Multiple Repeat Resections of Intra- and Extrahepatic Recurrencesin Patients Undergoing Initial Hepatectomy for Colorectal CarcinomaMetastases , 2002, World Journal of Surgery.

[178]  Rieken,et al.  [Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer]. , 2001, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].

[179]  E. Van Cutsem,et al.  Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[180]  R. Peto,et al.  Adjuvant radiotherapy for rectal cancer: a systematic overview of 8507 patients from 22 randomised trials , 2001, The Lancet.

[181]  K. Hase,et al.  Prognostic Determinants of Patients With Lateral Nodal Involvement by Rectal Cancer , 2001, Annals of surgery.

[182]  J. Tjandra,et al.  Consensus statement of definitions for anorectal physiology and rectal cancer , 2001, Diseases of the colon and rectum.

[183]  E Harrison,et al.  Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[184]  T. Sakaguchi,et al.  Impact of repeat hepatectomy on recurrent colorectal liver metastases. , 2001, Surgery.

[185]  陆星华,et al.  Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis , 2001 .

[186]  R. Warren,et al.  Current management of colorectal liver metastases. , 2000, Surgical oncology clinics of North America.

[187]  M. Ueno,et al.  Lateral node dissection and total mesorectal excision for rectal cancer , 2000, Diseases of the colon and rectum.

[188]  P. Sugarbaker,et al.  Treatment of primary colon cancer with peritoneal carcinomatosis , 2000, Diseases of the colon and rectum.

[189]  P. Simmonds,et al.  Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis , 2000, BMJ : British Medical Journal.

[190]  J. McCall,et al.  Surgery for colorectal liver metastases with hepatic lymph node involvement: a systematic review , 2000 .

[191]  L Pagliaro,et al.  Preoperative radiotherapy for resectable rectal cancer: A meta-analysis. , 2000, JAMA.

[192]  C. Wilson,et al.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[193]  Takashi Shibata,et al.  Microwave coagulation therapy for multiple hepatic metastases from colorectal carcinoma , 2000, Cancer.

[194]  K. Haruma,et al.  Conditions of curability after endoscopic resection for colorectal carcinoma with submucosally massive invasion. , 2000, Oncology reports.

[195]  R. Barth,et al.  Interval hepatic resection of colorectal metastases improves patient selection. , 2000, Archives of surgery.

[196]  R. James,et al.  Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial , 2000, The Lancet.

[197]  D. Weinberg,et al.  Surveillance after colorectal cancer resection , 2000, The Lancet.

[198]  T. Ishihara,et al.  Surgical treatment for both pulmonary and hepatic metastases from colorectal cancer. , 1999, The Journal of thoracic and cardiovascular surgery.

[199]  K. Sugihara,et al.  Repeat liver resection for recurrent colorectal liver metastases. , 1999, American journal of surgery.

[200]  R. Steele,et al.  Adjuvant radiotherapy for rectal cancer , 1999, The British journal of surgery.

[201]  P. Adeleine,et al.  Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[202]  E. Arbit,et al.  Resection of brain metastases from colorectal carcinoma in 73 patients , 1999, Cancer.

[203]  H. Konno,et al.  Resection of hepatic metastases of colorectal carcinoma: 20 years' experience. , 1999, Journal of hepato-biliary-pancreatic surgery.

[204]  M. Yasuno,et al.  Radical resection with autonomic nerve preservation and lymph node dissection techniques in lower rectal cancer surgery and its results: the impact of lateral lymph node dissection , 1998, Langenbeck's Archives of Surgery.

[205]  Christian Jacques,et al.  Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer , 1998, The Lancet.

[206]  R. Labianca,et al.  Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer , 1998, The Lancet.

[207]  J. Watari,et al.  Invasion depth diagnosis of depressed type early colorectal cancers by combined use of videoendoscopy and chromoendoscopy. , 1998, Gastrointestinal endoscopy.

[208]  J P Pignon,et al.  Results of 136 curative hepatectomies with a safety margin of less than 10 mm for colorectal metastases , 1998, Journal of surgical oncology.

[209]  K. Sugihara,et al.  Resection of both hepatic and pulmonary metastases in patients with colorectal carcinoma , 1998, Cancer.

[210]  L. Spaggiari,et al.  Surgical treatment of hepatic and pulmonary metastases from colorectal cancers. , 1998, The Annals of thoracic surgery.

[211]  D. Kandioler,et al.  Long-term results after repeated surgical removal of pulmonary metastases. , 1998, The Annals of thoracic surgery.

[212]  P. Lavin,et al.  Surgical margin in hepatic resection for colorectal metastasis: a critical and improvable determinant of outcome. , 1998, Annals of surgery.

[213]  J. Watari,et al.  Early nonpolypoid colorectal cancer: radiographic diagnosis of depth of invasion. , 1997, Radiology.

[214]  A. Hölscher,et al.  Significance of lymph node involvement at the hepatic hilum in the resection of colorectal liver metastases , 1997, The British journal of surgery.

[215]  K. Okuno,et al.  The extent of lymph node dissection for colon carcinoma , 1997, Cancer.

[216]  L Påhlman,et al.  Improved survival with preoperative radiotherapy in resectable rectal cancer. , 1997, The New England journal of medicine.

[217]  W. Enker,et al.  Liver resection for colorectal metastases. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[218]  L Gaspar,et al.  Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. , 1997, International journal of radiation oncology, biology, physics.

[219]  P. Rougier,et al.  Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[220]  T. Akasu,et al.  Pelvic autonomic nerve preservation for patients with rectal carcinoma: Oncologic and functional outcome , 1996, Cancer.

[221]  M. Tsuboi,et al.  Pulmonary resection for metastatic colorectal cancer: experiences with 159 patients. , 1996, The Journal of thoracic and cardiovascular surgery.

[222]  T. Cascino,et al.  Brain metastases from colorectal carcinoma: The long term survivors , 1996, Cancer.

[223]  G. Buess,et al.  Local therapy of rectal tumors , 1996, Diseases of the colon and rectum.

[224]  V. Sondak,et al.  Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. , 1996, Journal of the National Cancer Institute.

[225]  R. Aitken,et al.  Mesorectal excision for rectal cancer , 1996, The British journal of surgery.

[226]  H. Thaler,et al.  Total mesorectal excision in the operative treatment of carcinoma of the rectum. , 1995, Journal of the American College of Surgeons.

[227]  K. Shirouzu,et al.  Distal spread of rectal cancer and optimal distal margin of resection for sphincter‐preserving surgery , 1995, Cancer.

[228]  J. P. Pignon,et al.  Efficacy of adjuvant fluorouracil and folinic acid in colon cancer International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators , 1995, The Lancet.

[229]  S. Hirohashi,et al.  Pathologic Support for Limited Hepatectomy in the Treatment of Liver Metastases from Colorectal Cancer , 1995, Annals of surgery.

[230]  E. Bodner,et al.  Survival after surgical treatment of recurrent carcinoma of the rectum. , 1994, Journal of the American College of Surgeons.

[231]  B. Nordlinger,et al.  Survival benefit of repeat liver resections for recurrent colorectal metastases: 143 cases. Association Francaise de Chirurgie. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[232]  L D Lunsford,et al.  A multi-institutional experience with stereotactic radiosurgery for solitary brain metastasis. , 1994, International journal of radiation oncology, biology, physics.

[233]  A. Stiggelbout,et al.  Follow‐Up of Patients with Colorectal Cancer A Meta‐Analysis , 1994, Annals of surgery.

[234]  S. Kudo,et al.  Endoscopic Mucosal Resection of Flat and Depressed Types of Early Colorectal Cancer , 1993, Endoscopy.

[235]  H. Friza.  Report of a WHO Expert Committee. (WHO Technical Report Series No. 807), VI. World Health Organization, Geneva (1991), 65 pages, Soft cover SFr. 11 , 1993 .

[236]  W. Scheithauer,et al.  Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. , 1993, BMJ.

[237]  J. Scheele.  Hepatectomy for liver metastases , 1993, The British journal of surgery.

[238]  V. Rusch,et al.  Lung resection for colorectal metastases. 10-year results. , 1992, Archives of surgery.

[239]  P. Pairolero,et al.  Colorectal lung metastases: results of surgical excision. , 1992, The Annals of thoracic surgery.

[240]  C. Akinsanya.  Cancer pain relief and palliative care , 1992 .

[241]  Y Maruyama,et al.  A randomized trial of surgery in the treatment of single metastases to the brain. , 1990, The New England journal of medicine.

[242]  R. Tsuchiya,et al.  Surgical resection of pulmonary metastases from colorectal cancer. 10‐year follow‐up , 1989, Cancer.

[243]  K. Hojo,et al.  Significance of lateral node dissection for advanced rectal carcinoma at or below the peritoneal reflection , 1989, Diseases of the colon and rectum.

[244]  M. Ragozzino.  Detection and surveillance of colorectal cancer. , 1989, JAMA.

[245]  N. Petrelli,et al.  A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[246]  J. Ranstam,et al.  Pattern of recurrence in liver resection for colorectal secondaries , 1987, World Journal of Surgery.

[247]  K. Hughes,et al.  Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. , 1986, Surgery.

[248]  J. Fortner,et al.  Multivariate Analysis of a Personal Series of 247 Consecutive Patients with Liver Metastases from Colorectal Cancer: I. Treatment by Hepatic Resection , 1984, Annals of surgery.

[249]  Jinnai Dennosuke,et al.  General rules for clinical and pathological studies on cancer of the colon, rectum and anus , 1983 .

[250]  R. Heald,et al.  The mesorectum in rectal cancer surgery—the clue to pelvic recurrence? , 1982, The British journal of surgery.

[251]  K. Hojo,et al.  Lymphatic spread and its prognostic value in patients with rectal cancer. , 1982, American journal of surgery.

[252]  R. Gelber,et al.  The palliation of brain metastases in a favorable patient population: a randomized clinical trial by the Radiation Therapy Oncology Group. , 1981, International journal of radiation oncology, biology, physics.

[253]  E. PeñaydelaPeña,et al.  [Cancer of the rectum]. , 1955, Revista de sanidad militar.

[254]  G. Fontanini,et al.  FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. , 2014, European journal of cancer.

[255]  Gerald Gartlehner,et al.  [GRADE guidelines 15: going from evidence to recommendation - determinants of a recommendation's direction and strength]. , 2014, Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen.

[256]  R. Greil,et al.  Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. , 2013, The Lancet. Oncology.

[257]  Merina Ahmed,et al.  Stereotactic body radiotherapy for oligometastases. , 2013, The Lancet. Oncology.

[258]  C. Camma',et al.  Preoperative Radiotherapy for Resectable Rectal Cancer , 2013 .

[259]  Gerald Gartlehner,et al.  [GRADE guidelines: 10. Considering resource use and rating the quality of economic evidence]. , 2013, Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen.

[260]  Gerald Gartlehner,et al.  [GRADE guidelines: 8. Rating the quality of evidence - indirectness]. , 2012, Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen.

[261]  Gerald Gartlehner,et al.  [GRADE guidelines: 7. Rating the quality of evidence - inconsistency]. , 2012, Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen.

[262]  R. Greil,et al.  First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer , 2011, Journal of Cancer Research and Clinical Oncology.

[263]  M. Hollands,et al.  A Systematic Review of Clinical Response and Survival Outcomes of Downsizing Systemic Chemotherapy and Rescue Liver Surgery in Patients with Initially Unresectable Colorectal Liver Metastases , 2012, Annals of Surgical Oncology.

[264]  A. Kim,et al.  Extensive lymphadenectomy in colorectal cancer with isolated para‐aortic lymph node metastasis below the level of renal vessels , 2010, Journal of surgical oncology.

[265]  Jong-Hee Chang,et al.  Brain metastases from colorectal carcinoma: prognostic factors and outcome , 2010, Journal of Neuro-Oncology.

[266]  C. Fuchs,et al.  Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[267]  P. Jänne,et al.  EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[268]  P. Kim,et al.  Radiofrequency Ablation for Metachronous Liver Metastasis from Colorectal Cancer after Curative Surgery , 2007, Annals of Surgical Oncology.

[269]  J. Tuech,et al.  Repeat hepatectomy for recurrent colorectal liver metastases , 2006, Journal of surgical oncology.

[270]  Professor Jinnai Dennosuke President.  General rules for clinical and pathological studies on cancer of the colon, rectum and anus , 2006, The Japanese journal of surgery.

[271]  F. Kabbinavar,et al.  Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[272]  M. Salvati,et al.  Single cerebral metastasis from colorectal adenocarcinoma , 2003, Neurosurgical Review.

[273]  W. Jarnagin,et al.  Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases , 2003, Journal of Gastrointestinal Surgery.

[274]  L. Påhlman.  Adjuvant radiotherapy for rectal cancer: a systematic overview of 8507 patients from 22 randomised trials. Commentary , 2001 .

[275]  Ccg colorectal.  Adjuvant radiotherapy for rectal cancer: a systematic overview of 8507 patients from 22 randomised trials. , 2001 .

[276]  E. Blackstone,et al.  Is resection of pulmonary and hepatic metastases warranted in patients with colorectal cancer? , 1999, The Journal of thoracic and cardiovascular surgery.

[277]  大腸癌研究会.  Multi-institutional registry of large bowel cancer in Japan , 1992 .

[278]  Active Supportive Care.  Cancer pain relief and palliative care. Report of a WHO Expert Committee. , 1990, World Health Organization technical report series.

[279]  U. Metzger.  Adjuvant therapy for colon and rectal cancer. NIH Consensus Development Conference. , 1990, European journal of cancer.

[280]  Adjuvant therapy for patients with colon and rectum cancer. , 1990, Consensus statement. National Institutes of Health Consensus Development Conference.

[281]  E. Keeffe,et al.  Detection and surveillance of colorectal cancer. , 1989, JAMA.

[282]  H. Bismuth,et al.  Surgery for synchronous hepatic metastases of colorectal cancer. , 1988, Scandinavian journal of gastroenterology. Supplement.

[283]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[284]  R. Gelber,et al.  The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. , 1980, International journal of radiation oncology, biology, physics.

[285]  C. Morgan.  Cancer of the rectum. , 1951, Annals of the Royal College of Surgeons of England.